UroGen Pharma (URGN) Net Margin: 2017-2025
Historic Net Margin for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to -121.34%.
- UroGen Pharma's Net Margin fell 2742.00% to -121.34% in Q3 2025 from the same period last year, while for Sep 2025 it was -170.59%, marking a year-over-year decrease of 4147.00%. This contributed to the annual value of -140.35% for FY2024, which is 1674.00% down from last year.
- UroGen Pharma's Net Margin amounted to -121.34% in Q3 2025, which was up 41.16% from -206.24% recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Net Margin registered a high of -93.93% during Q3 2024, and its lowest value of -346.49% during Q1 2021.
- In the last 3 years, UroGen Pharma's Net Margin had a median value of -152.71% in 2024 and averaged -147.35%.
- Its Net Margin has fluctuated over the past 5 years, first surged by 56,644bps in 2021, then crashed by 5,335bps in 2025.
- Quarterly analysis of 5 years shows UroGen Pharma's Net Margin stood at -175.91% in 2021, then skyrocketed by 1,634bps to -159.57% in 2022, then spiked by 4,900bps to -110.57% in 2023, then tumbled by 4,214bps to -152.71% in 2024, then slumped by 2,742bps to -121.34% in 2025.
- Its last three reported values are -121.34% in Q3 2025, -206.24% for Q2 2025, and -216.47% during Q1 2025.